Aldatu Biosciences Receives $1.5 Million Direct-to-Phase II SBIR Grant from the NIAID for HIV Drug Resistance Diagnostic Development

Cambridge, MA, 12th March 2015 (download press release .pdf) Aldatu Biosciences, a novel diagnostics platform company focused on improving HIV patient care globally, today announced it has been awarded a Direct-to-Phase II Small Business Innovation Research (SBIR) grant for approximately $1,500,000 over two years. Supported by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health …